Teva and Xenon ’s Phase II trial of TV-45070 for PHN fails to meet endpoints

Teva Pharmaceutical Industries and Xenon Pharmaceuticals have reported top-line data from a Phase II clinical trial of TV-45070 to treat patients suffering from post-herpetic neuralgia (PHN), with the drug failing to meet required endpoints.

Source: Drug Development Technology - June 27, 2017 Category: Pharmaceuticals Source Type: news